1-(4-氯苯甲酰基)-3-甲基哌啶 | 19202-07-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氯苯甲酰基)-3-甲基哌啶
• 英文名称: 1-(4-chloro-benzoyl)-3-methyl-piperidine
• 英文别名: (4-Chlorophenyl)-(3-methylpiperidin-1-yl)methanone
• CAS: 19202-07-4
• 化学式: C₁₃H₁₆ClNO
• mdl: MFCD00158565
• 分子量: 237.729
• InChiKey: JLONTIZITXBHKW-UHFFFAOYSA-N

物化性质

• 沸点：
  367.1±25.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯甲酰基)-3-甲基哌啶 、 对氯苯胺 在 溶剂黄146 作用下， 以 水 为溶剂， 反应 18.0h， 生成 (4-(4-Chlorophenylamino)phenyl)(3-methylpiperidin-1-yl)methanone
  参考文献：
  名称：

  Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity

  摘要：

  High throughput screening led to the identification of nicotinamide derivative 2 as a structurally novel mGluR5 antagonist. Optimization of the modular scaffold led to the discovery of 16m, a compound with high affinity for mGluR5 and excellent selectivity over other glutamate receptors. Compound 16m exhibits a favorable PK profile in rats, robust anxiolytic-like effects in three different animal models of fear and anxiety, as well as a good PK/PD correlation. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.001
• 作为产物：
  描述：

  4-氯苯甲酰氯 、 3-甲基哌啶 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1-(4-氯苯甲酰基)-3-甲基哌啶
  参考文献：
  名称：

  Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity

  摘要：

  High throughput screening led to the identification of nicotinamide derivative 2 as a structurally novel mGluR5 antagonist. Optimization of the modular scaffold led to the discovery of 16m, a compound with high affinity for mGluR5 and excellent selectivity over other glutamate receptors. Compound 16m exhibits a favorable PK profile in rats, robust anxiolytic-like effects in three different animal models of fear and anxiety, as well as a good PK/PD correlation. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.001

文献信息

• USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF)
  申请人：Public University Corporation Yokohama City University

  公开号：EP2535059A1

  公开（公告）日：2012-12-19

  The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g., a compound represented by the following formula (I), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof: wherein n represents 0 or 1; R1, R2, R3, R4 and R5 each independently represent a hydrogen atom, a hydrocarbon group or a functional group; Y represents a single bond, a carbonyl group, -CONH-, -NHCO- or a sulfonyl group; and Z represents a nitrogen-containing heterocyclic group which may have a substituent, an amino group which may have a hydrocarbon group or an aromatic hydrocarbon group, or a nitrogen and oxygen-containing heterocyclic group which may have a substituent.

  本发明确定了一种能与mSin3B的PAH1结构域结合的化合物，该化合物能特异性地与神经限制性沉默因子NRSF结合，并将该化合物用作预防和/或治疗与神经限制性沉默因子NRSF/REST异常表达或NRSF/REST靶向基因异常表达相关的疾病，如亨廷顿氏病、髓母细胞瘤和神经性疼痛。 本发明提供了一种药物组合物，该药物组合物包含一种能够与 mSin3B 的 PAH1 结构域结合的物质，例如由下式（I）代表的化合物、其药理学上可接受的盐或其药理学上可接受的酯： 其中 n 代表 0 或 1；R1、R2、R3、R4 和 R5 各自独立地代表氢原子、烃基或官能团；Y 代表单键、羰基、-CONH-、-NHCO- 或磺酰基；Z 代表可能具有取代基的含氮杂环基、可能具有烃基或芳香烃基的氨基或可能具有取代基的含氮和氧杂环基。
• Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity
  作者：Carsten Spanka、Ralf Glatthar、Sandrine Desrayaud、Markus Fendt、David Orain、Thomas Troxler、Ivo Vranesic

  DOI：10.1016/j.bmcl.2009.11.001

  日期：2010.1

  High throughput screening led to the identification of nicotinamide derivative 2 as a structurally novel mGluR5 antagonist. Optimization of the modular scaffold led to the discovery of 16m, a compound with high affinity for mGluR5 and excellent selectivity over other glutamate receptors. Compound 16m exhibits a favorable PK profile in rats, robust anxiolytic-like effects in three different animal models of fear and anxiety, as well as a good PK/PD correlation. (C) 2009 Elsevier Ltd. All rights reserved.